European Parliament

2014-2019



Plenary sitting

B8-0101/2017

9.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure on health risks associated with proton pump inhibitors

Mireille D'Ornano

RE\1114608EN.docx PE598.409v01-00

B8-0101/2017

Motion for a European Parliament resolution on health risks associated with proton pump inhibitors

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas proton pump inhibitors ('inhibitors') are among the medicines most prescribed for gastroesophageal reflux worldwide;
- B. whereas a team of researchers at the University of Stanford in the USA has studied the impact of inhibitors on human health and demonstrated a probable causal link with increased risk of myocardial infarction in the general population (10 June 2015);
- C. whereas, according to the same study, H2 blockers are an alternative solution, as they are not associated with increased cardiovascular risk;
- 1. Encourages the Commission to issue advisory guidelines on H2 blockers, and encourages Member States to review their national legislation on inhibitors.

